The incidence and mortality rates for prostate cancer keep stabilizing or decreasing in many parts of the world. Despite this trend, prostate cancer still is the second commonly diagnosed cancer as well as the sixth leading cause of cancer mortality among men. The prostate cancer patients’ survival rate depends on how far the disease has spread.
Studies have revealed that the significant variations are due to factors such as availability of improved treatments, detection practices, and genetic factors.
According to the study:
- After examining the incidence and mortality patterns for prostate cancer across five continents, the rates had decreased and stabilized in most countries. The researchers used recent cancer incidence data from the International Agency for Research on Cancer while the World Health Organization provided the mortality data.
- Researchers examined long term trends from 38 countries that had accurate, timely and complete information. The short term trends came from 44 countries that had available incidence data while the mortality data came from 71 countries.
- Of the 71 countries analyzed for mortality rates, a decrease was seen in 14 countries, an increase in three countries while 54 countries showed stability.
- Out of 44 countries that were examined for incidence of prostate cancer, the rates for the recent five years increased in four countries. Bulgaria showed the most substantial increase. Seven of the countries showed a decrease, with the US having a significant decline. The rest of the 33 countries showed stability.
- Statistics show that many nations have achieved stability in the rates for prostate cancer and these rates have not increased during the examination period. Researchers are hoping that many more nations will be moving stability to lower incidence and mortality rates in the coming years.
The study confirmed that PSA screening contributed mainly to the decline in prostate cancer incidence rates. And since PSA screening is not available in low-income countries, diagnosis is performed at later stages leading to increased mortality rates. Future studies will be tailored to monitoring the mortality rates and late-stage prostate cancer in order to assess the impact of PSA testing reductions in some countries.